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Abstract: Observational studies consistently find an inverse relationship between whole-grain intake
and weight gain. We aimed to confirm this in an open-label researcher-blinded parallel design
randomised trial. A total of 179 overweight/obese women with a habitually low whole-grain intake
(<16 g/day) were randomised to a weight maintenance diet with refined-grain (RG) or whole-grain
(WG) foods (80 g/day) for 12 weeks after an initial weight loss program over 8 weeks. Body weight
and composition was assessed at baseline, after the initial weight loss, and after the 12-week dietary
intervention. During the 12-week dietary intervention phase, there were no group differences in
changes in body weight and total fat mass %, whereas abdominal fat mass tended to increase
more during the dietary intervention phase in the WG compared to the RG group (0.7 (SD 3.6) vs.
−0.3 (SD 3.8) %; p = 0.052). Plasma alkylresorcinol concentrations, biomarkers of wholegrain wheat
and rye intake, indicated poor compliance, particularly in the WG group, where >60% of participants
had alkylresorcinol concentrations below 70 nmol/L, a concentration indicating low or no intake of
whole-grain wheat. Further, weight regain was lower than expected in both intervention groups,
further supporting a lack of compliance to the post-weight-loss diet. The rate of compliance was too
low to conclude any effect of whole grain on weight maintenance, and reinforces the need to use
objective measures of compliance in nutrition intervention studies.
Keywords: whole grain; weight maintenance; compliance; biomarkers; alkylresorcinols
1. Introduction
Greater whole-grain intake is associated with reduced weight gain and lower body mass index
(BMI) in several observational studies [1–17], though not all [18–21]. Other observational studies have
found a healthier body fat distribution is also associated with greater intake of whole grains [15,22].
While the effect size is small (around 0.3 kg less weight gain for highest vs. lowest intakes of whole
grains [6]), this may still have an important impact on the prevention of obesity related diseases.
Although the inverse relationship between intake of whole grains and weight gain is generally
consistent, there is still room for residual confounding due to the association of whole-grain intake
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with a healthy lifestyle, even if this has been factored into the models. These associations have been
tested in several intervention trials of varying designs to determine if whole grains may aid weight
loss or loss of fat. Results from these trials are mixed, with some studies indicating greater weight loss
or loss of body fat when subjects are fed whole grains rather than refined grains [23–26], and others
finding no advantage [27]. A recent meta-analysis of intervention trials examining whole grains and
their effect on weight loss and body composition found that there was no overall effect on weight,
but a small effect for increasing fat loss (−0.48%) in the limited number of trials that have assessed this
variable [28].
Study designs vary widely among these studies, which have included whole grain intake against
a background of both hypocaloric and isocaloric diets, different amounts of whole grains, and different
types of grain. This heterogeneity in design complicates the overall evaluation of the evidence, and also
raises an additional problem in that study design and location/population potentially have a major
effect on dietary compliance. Katcher et al. identified the problem of subjects adding whole grains to
their diet, rather than replacing current foods with whole grains [24], an issue that was also highlighted
by Brownlee et al. [29] in a large-scale intervention of nearly 300 subjects. This leads to increased
overall energy intake, which would nullify any benefit of choosing whole grains over refined grains.
The issue of compliance in nutritional intervention studies is well known, especially in free-living
settings, and over longer periods of time [30–33]. Using biomarkers of food intake has been proposed
as one way of ensuring compliance in whole-grain intervention studies [34], and by measuring plasma
alkylresorcinols, it is possible to monitor likely compliance to whole-grain interventions based on
wheat and rye. Ideally, a biomarker should be used together with a validated dietary assessment
tool, though there are several issues with this approach—mainly what compliance measurement tool
should take precedence: self-reported recall or a non-subjective measurement from a biofluid, and how
to handle wide variation in intra-individual biomarker response. To date, plasma alkylresorcinols
have been used as biomarkers of compliance in several studies [23,35–37]. In these four studies, diet
effects were observed for primary or secondary outcomes, and compliance as determined by plasma
alkylresorcinol concentrations was high. While relatively expensive to use for large-scale intervention
trials, it is possible that plasma alkylresorcinols can provide an added level of surety when assessing
the results of nutrition intervention trials.
In order to assess whether findings from observational studies that whole grains reduce weight
gain can be replicated in an intervention trial setting, we performed a randomised parallel design
researcher-blinded intervention trial in overweight and obese women where the primary objective was
to assess abdominal fat regain over three months after an initial weight loss. Secondary outcomes were
changes to body weight, clinical chemistry markers, and plasma alkylresorcinols as well as nutritional
intake and gastrointestinal symptoms.
2. Methods
2.1. Study Design
The study was a parallel group design based at a single study centre (Grenoble, France). The study
was divided into three phases. The study design is presented graphically in Figure 1. During the first
phase, participants were instructed to follow a low-calorie diet (LCD) (1200 kcal/day) with the aim to
lose 6% of their body weight in 8 weeks. Participants who were successful in this goal (n = 178) were
then randomised onto one of two ad libitum diets by block-randomisation (block size, n = 4). There
was a 1-week run-in period between the LCD phase and the start of the dietary intervention, where
all participants were provided with refined-grain foods (and no whole-grain foods) to put them on
an equal starting point for cereal food intake after the weight loss phase. The two intervention diets
were based on either eating at least 80 g of whole grain per day or the equivalent as refined grains for
12 weeks, based on foods provided by the study centre. The participants and dieticians who assessed
compliance to the intervention diets were not blinded during the intervention, but outcome assessors
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as well as statisticians were blinded until data analyses were completed. The study was approved
by both the regional ethical committee (C.P.P. Sud-Est III) and the Health Authorities (ANSM), and
carried out according to the Declaration of Helsinki. All subjects provided written informed consent
for participation in the study. The study was registered at clinicaltrials.gov (NCT01239147).
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2.2. Participants
Overweight and obese (body mass index (BMI): 27–34 kg/m2) women between the ages of 20 and
50 were recruited for this study from the Grenoble region of France. Only women were selected for this
trial in order to reduce potential heterogeneity due to gender. Participant inclusion criteria were age
(20–50 years), healthy (determined by clinical exami ation and medical history), pre-menopause, BMI
(27–34 kg/m2), w ist circumference (>80 cm), no special diet in the previous 3 months, normal blood
pressure and heart rate (systolic 95–140 mmHg; diastolic 50–90 mmHg), low h bitual whole-grain
intake (<16 g/day determi ed using a previously validated questionnaire for a French-speaking
population [38]). Exclusion criteria beyond being out of the range of the inclusion criteria were: history
of metabolic disease including type 2 diabetes, renal insufficiency, taking medication or supplements
to aid weight loss, a variable medication regime, pregnancy or breast feeding, participation in a
remunerated clinical trial within the previous 12 months, and known food allergies of relevance to
the project.
2.3. Experimental Diet
During the weight loss phase, participants were provided with commercially available weight
loss products (Nestlé Protéika®, Nestlé SA, Paris, France), consisting of bars, shakes, and ready-to-eat
meals, along with advice from a dietician on how to incorporate these foods into their diet and restrict
their daily energy intake to 1200 kcal/day. The weight loss regime was the same for all participants,
independent of body size and physical activity level.
Following the LCD period, participants were randomised onto a whole-grain (WG) diet or a
refined-grain (RG) diet, with dietary advice to help them to maintain their weight. Whole-grain and
refined-grain products were provided to the subjects in a supermarket s tting (“shop”) at th study
site, where they coul ake products ad libitum. The shop w s ivided into two sections: one with
whole-grain products, the other with refined-grain products. Subjects came to the study site once
per week t choose food items appropriate for their dietary group, and a dietician recorded all food
items taken from the shop. Whole grain was defined based on the Health Grain Foru definition [39],
that all parts of the grain were present in the products in their correct proportions, allowing for some
minor losses of bran. The proportion of whole grains in products was based on that reported by
manufacturers on the product packaging, and confirmed by analysis of alkylresorcinols in the case
of the wheat and rye products [40]. Participants in the WG group were asked to include at least 80 g
of whole grains per day during the WG period. The whole-grain products provided included bread,
breakfast cereal, pasta, rice, couscous, and muesli bars; each product had between 25% and 100% whole
grain by weight. Participants on the refined-grain diet were provided equivalent non-whole-grain
foods to select from. Details of the foods provided in the study are in Supplementary Materials
Table S1.
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2.4. Nutritional Counselling
During all phases of the study, the participants met with a trained dietician to receive nutritional
advice on a weekly basis. In case of holiday or similar events, the dietary counselling was done by
telephone. During the 8-week LCD period, they were instructed on how to keep to a calorie-restricted
diet (1200 kcal/day) and incorporate the LCD products into their habitual diet. During the 12-week
weight-maintenance period, participants in both treatment groups received nutritional counselling on
how to incorporate the refined-grain and whole-grain products, respectively, into their diet and not
to change their dietary habits beyond this. Particular attention was paid to helping subjects on the
whole-grain intervention of replacing refined-grain food items in their diet by emphasising substitution
rather than addition of these foods. Furthermore, all participants were instructed to maintain their
physical activity level throughout the study. Individual energy requirements were assessed using
the Schofield equation based on weight reached after the weight loss phase and assuming a low
activity factor (1.3). The same level of dietary counselling was offered to all participants, irrespective
of group allocation.
2.5. Dietary Intake Assessment
Intake of refined-grain and whole-grain foods was monitored by review of daily recordings done
by the participants. Furthermore, participants filled in a 3-day food record prior to the start of the study
(visit 1) and towards the end of the dietary intervention (visit 4). Subjects also reported satisfaction
with the diets using a validated 45-item questionnaire previously used in a whole-grain intervention
study [24], and level of physical activity was assessed using Baecke’s short questionnaire [41] at visits 1,
3 and 4.
2.6. Anthropometric Measurements
All measurements were performed in the morning after ≥10 h fasting and after voiding of the
bladder. Body weight was measured on an electronic scale to the nearest 0.1 kg (TBF300, TANITA Corp.,
Tokyo, Japan), while the participants were wearing light clothing and no shoes. Height was measured
to the nearest 0.5 cm by using a wall-mounted stadiometer without shoes. Waist circumference was
measured midway between the anterior superior iliac spine and the base of the last rib, while hip
circumference was measured at the widest posterior extension of the buttocks. Both were measured
to the nearest 0.5 cm. Sagittal abdominal diameter (SAD) was measured once to the nearest 0.1 cm.
Body composition was measured before and after the dietary intervention period by dual-energy
X-ray absorptiometry (DEXA) scanning (Lunar Radiation Co., General Electric, Madison, WI, USA),
and fat-free mass (FFM) was calculated as total body mass − fat mass (FM). Abdominal fat mas was
directly computed using anatomical reference measures, and reported as % of total fat as measured
by DEXA.
2.7. Biochemical Measurements
Blood samples were collected with both lithium heparin and ethylenediaminetetraacetic acid
(EDTA) as anticoagulants, and plasma was separated by centrifugation at 1000× g for 10 min at 4 ◦C.
Samples were aliquoted and stored at −80 ◦C before analysis. Plasma total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglycerides, glucose, high-sensitivity C-reactive protein (hsCRP),
glycated haemoglobin, insulin, leptin, adiponectin, and plasminogen activation inhibitor 1 (PAI-1) were
measured using validated standard enzyme linked immunoassays. All clinical chemistry parameters
were analysed in a blinded manner by a third-party laboratory. Plasma alkylresorcinols were measured
using normal-phase liquid chromatography coupled to a tandem mass spectrometer using a previously
validated method [42]. Plasma total alkylresorcinol concentrations >70 nmol/L were taken as a
conservative cutoff for compliance for both groups, based on data from controlled diet studies [34].
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Alkylresorcinols in study foods were analysed using high-performance liquid chromatography with
fluorescence detection [40].
2.8. Statistical Analyses
Sample size estimation was based on demonstrating a difference in mean body fat mass
maintenance after an initial loss of fat mass at a significance level of 5% and with a statistical power of
80%. The initial calculations suggested that by including 80 participants in each group, we would be
able to detect a difference in body fat mass of 1.8 (SD 4.0) kg. In addition, we anticipated a dropout
rate of <10% during the dietary intervention, thus we aimed to enrol at least 88 participants into each
group. Due to a lack of previous studies on whole grains and abdominal fat loss at the time the study
was planned, power calculations were only done for loss of total body fat. All statistical analyses were
performed in SAS® System for Windows (release 9.4, SAS Institute Inc., Cary, NC, USA). Homogeneity
of variance and normal distribution were inspected using residuals plots, normal probability plots,
and histogram.
Group comparisons of variables assessed at baseline (visit 1) and prior to the dietary intervention
(visit 3) as well as dropout rate were done using a one-way ANOVA or Mann–Whitney Wilcoxon tests,
as appropriate, for quantitative parameters, and a chi-squared (χ2) or Fisher’s exact test, as appropriate,
for qualitative parameters. Group differences in changes in outcomes assessed during the LCD phase
(between visits 1 and 2) and during the dietary intervention (between visits 3 and 4) were assessed
using a one-way ANCOVA with group (RG or WG) as a fixed variable and corresponding baseline
(visit 1 or 3) value and age as a covariate. Both complete case (CC) and intention-to-treat (ITT) analyses
were performed, but CC analyses were considered the primary analyses of interest. All data are
presented as means with SD unless otherwise indicated. Differences were considered significant at
p < 0.05.
3. Results
3.1. Flow of Participants during the Study
In total, 317 overweight or obese women were enrolled into the weight loss phase, of which
178 obtained a weight loss of ≥6% and were eligible for randomisation (Supplementary Materials
Figure S1). Thus, a total of 178 women were randomised to the RG group (n = 89) or the WG group
(n = 89), respectively. The dropout rate during the dietary intervention differed between the two groups
(p = 0.034), as 1 and 8 participants dropped out from the RG and WG groups, respectively. Even so,
there was no difference between ITT analyses and CC analyses in any of the outcomes assessed, thus
only results from the CC analyses are reported here. Reasons for subject dropouts were 6 premature
withdrawals, 2 subjects with positive pregnancy tests, and 1 inability to comply with the study diet.
Baseline characteristics of the subjects are presented in Table 1.
Table 1. Baseline characteristics of the participants (visit 1) in the whole-grain (WG) and refined-grain
(RG) groups (mean values and standard deviations (SD)).
RG Group (n = 88) WG Group (n = 81)
Mean SD Mean SD
Age (years) 35.3 8.7 36.2 10.1
Height (cm) 164.6 6.7 163.0 6.1
Weight (kg) 81.5 8.1 80.2 7.2
Body mass index (kg/m2) 30.1 2.0 30.2 1.9
Total body fat (%) 44.5 4.8 45.5 4.4
Abdominal body fat (%) 45.6 7.4 45.6 6.7
Whole-grain intake (g/day) 13.5 29.9 13.0 25.3
Current smokers (n) 28 20
Caucasian/Black/Asian/other (n/n/n/n) 81/5/1/1 76/4/0/1
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3.2. Dietary Intake and Compliance
Dietary intake data based on 3-day food records are presented in Table 2. There was no difference
at baseline for total energy and macronutrient intake. During the intervention, there was a higher
reported intake of dietary fibre and lower reported intake of fat in the WG group. Mean daily intake
of whole-grain foods in the RG and WG group after 12 weeks was reported to be 0.5 (SD 1.6) g
and 124 (SD 1.7) g, respectively (p < 0.0001). Based on a detailed diet analysis on a random selection of
six participants, the average (min; max) proportion of grains eaten on the WG diet was 79 (64; 90) %
wheat, 16 (6; 29) % rice, 4 (0; 12) % oats, and 1 (0; 6) % rye. The main grains eaten on the RG diet were
wheat and rice. Plasma alkylresorcinol concentrations were 119 (SD 181) nmol/L in the WG group
and 33.6 (SD 38.9) nmol/L in the RG group after the dietary intervention, and the change from visit 3
was significantly different between groups (p < 0.0001) (Table 3), even though 62% of the participants
in the WG group had plasma alkylresorcinol concentrations <70 nmol/L, which was applied as a
conservative cutoff for compliance (Figure 2). Plasma alkylresorcinols and reported whole-grain
intake in the WG group after the dietary intervention (visit 4), however, did not correlate (Spearman’s
correlation coefficient R = −0.02919; p = 0.85), which indicates poor compliance (Figure 3).
Table 2. Dietary intake data from 3-day food records of the participants at baseline (visit 1) and during
the last week of the dietary intervention (visit 4) in the whole-grain (WG) and refined-grain (RG)
groups (mean values and standard deviations (SD)).
Baseline During Dietary Intervention
RG Group (n 88) WG Group (n 81) RG Group (n 88) WG Group (n 81)
Mean SD Mean SD Mean SD Mean SD
Energy intake (kcal/day) 1759 472 1823 541 1402 396 1331 321
Protein (E%) 18.0 3.5 17.2 3.7 17.4 3.3 18.2 3.5
Fat (E%) 37.2 5.9 38.7 7.3 31.9 7.5 28.9 * 5.7
Carbohydrates (E%) 43.2 6.6 42.6 7.0 50.0 7.3 51.9 8.4
Dietary fibre (g/day) 13.6 5.2 13.8 5.1 13.3 4.1 18.5 * 5.2
Whole grain intake (g/day) 13.5 29.9 13.0 25.3 0.5 2.6 124 * 29
* Indicate significantly different changes in WG compared to RG group; p < 0.05.
Table 3. Mean values prior to (visit 3) and unadjusted changes in cardiometabolic outcomes and
plasma alkylresorcinols during the dietary intervention phase (visit 4–visit 3) in the whole-grain (WG)
and refined-grain (RG) groups (mean values with standard deviations (SD)).
RG Group (n 88) WG Group (n 81)
At Visit 3 ∆ Visit 4–Visit 3 At Visit 3 ∆ Visit 4–Visit 3
Mean SD Mean SD Mean SD Mean SD
Systolic blood pressure (mmHg) 111.2 10.0 0.2 10.0 109.8 10.2 1.0 9.3
Diastolic blood pressure (mmHg) 71.1 7.4 −1.2 7.6 71.0 8.3 0.0 8.5
Glucose (mmol/L) 4.78 0.41 −0.05 0.35 4.79 0.39 −0.07 0.49
Insulin (pmol/L) 61.1 36.8 −1.8 32.0 55.9 29.5 1.8 28.4
Glycated haemoglobin, HbA1C (%) 5.34 0.29 0.02 0.20 5.29 0.31 0.04 0.17
Total cholesterol (mmol/L) 4.39 0.79 0.47 0.57 4.62 0.88 0.42 0.74
LDL cholesterol (mmol/L) 2.72 0.69 0.21 0.46 2.90 0.79 0.19 0.60
HDL cholesterol (mmol/L) 1.29 0.29 0.22 0.21 1.29 0.26 0.18 0.23
Total triacylglycerol (mmol/L) 0.86 0.36 0.08 0.37 0.95 0.45 0.09 0.40
Leptin (µg/L) 19.8 9.4 4.3 7.7 18.3 11.2 6.7 7.9
Adiponectin (mg/L) 9.32 4.54 0.97 2.42 8.39 6.32 1.30 2.16
High sensitivity C-reactive protein(mg/L) 3.00 3.88 −0.06 2.92 3.32 6.63 0.67 7.54
Plasminogen activator inhibtior-1 (mmol/L) 12.81 5.40 2.96 3.13 12.62 6.13 3.36 10.44
Alkylresorcinols (nmol/L) 35.6 62.9 −2.0 70.4 47.6 109.2 71.2 199.0 *
* Indicates significantly different changes in WG compared to RG group; p < 0.0001.
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Figure 2. Mean and individual plasma alkylresorcinol concentration (nmol/L) for individuals by
intervention at visit 1 (at baseline), visit 3 (after the low-calorie diet (LCD) and run-in periods), and visit
4 after the 12-week dietary intervention with either refined (RG) or wholegrain (WG) foods. For clarity,
four subjects with plasma alkylresorcinol concentrations >500 nmol/L at visit 4 in the WG group have
not been included.
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Figure 3. Correlation between reported mean whole-grain intake (g/day) during the 12-week dietary
intervention and plasma alkylresorcinol concentration (nmol/L) measured at visit 4 with 95%
confidence intervals for participants in the WG group (n 81).
There was no difference in the overall diet satisfaction score prior to the dietary intervention
phase (visit 3) (3.7 (SD 0.5) vs. 3.7 (SD 0.4) in the RG and WG groups, respectively; p > 0.80). Both diets
were equally well accepted, as a small, but significant increase was seen in both groups during the
intervention, but no group difference was present (0.1 (SD 0.3) vs. 0.1 (SD 0.4) in the RG and WG
groups, respectively; p > 0.80).
3.3. Anthropometric Measures
Initial body weight and total and abdominal body fat % did not differ between groups (p = 0.27,
p = 0.30, and p = 0.16), and during the LCD phase the women lost 7.8 (SD 2.0) % and 7.6 (SD 1.9) %
of their body weight and 3.3 (SD 2.4) % and 3.8 (SD 2.2) % total body fat mass in the RG and WG
groups, respectively (Table 4). A slightly larger decrease, albeit not significant, in abdominal fat % was
seen during the LCD among women randomised to the WG group compared to those randomised to
the RG diet (−5.0 (SD 3.6) % vs. −4.2 (SD 3.7) %; p = 0.09), whereas changes in loss of body weight
(p = 0.48) and total fat mass % (p = 0.11) during the LCD phase did not differ between groups.
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Table 4. Mean values prior to (visit 3) and unadjusted changes in anthropometric outcomes during
the dietary intervention phase (visit 4–visit 3) in the whole-grain (WG) and refined grain (RG) groups
(mean values with standard deviations (SD)).
Refined Grain (n 88) Whole Grain (n 81)
At Visit 3 Visit 4–Visit 3 At Visit 3 Visit 4–Visit 3
Mean SD Mean SD Mean SD Mean SD
Body weight (kg) 74.9 7.7 0.4 2.7 73.9 6.6 0.4 2.3
Body Mass Index (kg/m2) 27.6 2.0 0.14 1.0 27.8 1.9 1.8 0.9
Total fat mass (%) 41.1 5.5 −0.2 2.9 41.7 5.0 0.4 2.3
Abdominal body fat (%) 45.6 7.4 −0.3 3.8 45.8 6.8 0.7 3.6
Sagittal abdominal diameter (cm) 19.5 1.7 0.1 1.2 19.3 1.7 0.3 0.9
Waist circumference (cm) 85.4 6.4 −0.1 4.2 85.6 6.8 0.0 3.2
Hip circumference (cm) 107.3 6.4 0.1 2.9 107.3 5.0 0.2 2.5
During the dietary intervention phase, body weight increased slightly in both groups, but changes
did not differ between groups (0.36 (SD 2.7) kg and 0.43 (SD 2.3) kg in the RG and WG groups,
respectively; p = 0.96. Further adjustment for body weight loss during the LCD phase did not
change this result. In contrast, abdominal fat mass tended to increase more during the dietary
intervention phase among women randomised to the WG compared to the RG group (0.7 (SD 3.6) %
vs. −0.3 (SD 3.8) %; p = 0.052) (Figure 4). Further adjustment for loss of abdominal fat mass during
the LCD phase only slightly attenuated this finding (p = 0.062). However, changes in total fat mass %
during the dietary intervention did not differ between groups (p = 0.11), and adjustment for loss of fat
mass during the LCD phase did not change the result (p = 0.11). Finally, changes in fat free mass, BMI,
waist and hip circumference, or SAD did not differ between the RG and WG groups.
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RG Group (n 88)  WG Group (n 81) 
At Visit 3  Δ Visit 4–Visit 3  At Visit 3  Δ Visit 4–Visit 3 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Systolic blood pressure (mmHg)  111.2  10.0  0.2  10.0  109.8  10.2  1.0  9.3 
Diastolic blood pressure (mmHg)  71.1  7.4  −1.2  7.6  71.0  8.3  0.0  8.5 
Glucose (mmol/L)  4.78  0.41  −0.05  0.35  4.79  0.39  −0.07  0.49 
Insulin (pmol/L)  61.1  36.8  −1.8  32.0  55.9  29.5  1.8  28.4 
Glycated haemoglobin, HbA1C (%)  5.34  0.29  0.02  0.20  5.29  0.31  0.04  0.17 
Total cholesterol (mmol/L)  4.39  0.79  0.47  0.57  4.62  0.88  0.42  0.74 
LDL cholesterol (mmol/L)  2.72  0.69  0.21  0.46  2.90  0.79  0.19  0.60 
HDL cholesterol (mmol/L)  1.29  0.29  0.22  0.21  .29  0.26  0.18  0.23 
Total triacylglycerol (mmol/L)    0.86  0.36  0.08  0.37  0.95  0.45  0.09  0.40 
Leptin (μg/L)  19.8  9.4  4.3  7.7  18.3  11.2  6.7  7.9 
Adiponectin (mg/L)  9.32  4.54  0.97  2.42  8.39  6.32  1.30  2.16 
High sensitivity C‐reactive protein(mg/L)  3.00  3.88  −0.06  2.92  3.32  6.63  0.67  7.54 
Plasminogen activator inhibtior‐1 (mmol/L)  12.81  5.40  2.96  3.13  12.62  6.13  3.36  10.44 
Alkylresorcinols (nmol/L)  35.6  62.9  −2.0  70.4  47.6  109.2  71.2  199.0 * 
* Indicates significantly different changes in WG compared to RG group; p < 0.0001.   
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and dietary intervention phase (visit 3–4). WG, whole grain; RG, refined grain; LCD, low calorie diet. Figure 4. Mean abdominal fat mass percentage with SD during the LCD and run-in phases (visit 1–3)and dietary intervention phase (visit 3–4). WG, whole grain; RG, refined grain; LCD, low calorie diet.
Post hoc, we explored the indication of poor compliance in the WG group by performing
regression models in order to identify the main determinants of loss of total and abdominal body fat.
Independent of diet allocation, plasma alkylresorcinols (at visit 4) were not associated with loss of total
or abdominal fat mass, nor body weight (data not shown). Furthermore, due to the potential lack of
compliance according to plasma concentration concentrations of alkylresorcinols, an analysis on only
the subgroup of compliant participants was conducted (<70 nmol/L for RG and >70 nmol/L for WG
at visit 4). For change of abdominal fat mass % during the dietary intervention, the difference between
groups was further attenuated when only including compliant participants (RG: n 76; WG: n 30) in
both groups (−0.44 (3.81) vs. 0.45 (3.95) % in the RG vs. WG group, respectively; p = 0.095), and not
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present among non-compliant participants. For change in body weight, a stratified analysis did not
change the result (0.37 (2.77) vs. 0.65 (2.44) % in the RG vs. WG group, respectively).
3.4. Cardiometabolic Outcomes
After 12 weeks of dietary intervention, there was no difference between the RG and WG groups
in changes of blood pressure, blood lipids, inflammatory markers, or markers of glucose metabolism
(all p-values > 0.20) (Table 3). We note here that the menstrual cycle was not controlled for, which can
have a major impact on the variability of these outcomes [43], and may obscure any findings beyond
those highlighted regarding compliance.
4. Discussion
In a study designed to investigate whether weight regain after weight loss could be reduced by
eating whole grains instead of refined grains, we found that >60% of the subjects randomised to the
whole-grain diet were unlikely to have complied to the diet. This prevents any conclusions on the
relationship between whole grains and the primary and secondary endpoints measured, but does
highlight the importance of using biomarkers of intake to check compliance in nutrition intervention
studies. Had these not been used, the only conclusion possible, that whole grains were found not to
have any effect on weight regain, would in fact not be supported by our trial based the numbers who
actually followed the prescribed protocol.
The use of biomarkers to monitor compliance in intervention studies can be controversial,
especially if other measures of compliance (e.g., diaries or questionnaires) indicate excellent compliance,
as was the case in this study. Which measure takes precedence? As plasma alkylresorcinols are
non-subjective, they are not affected by a subject’s perception of what they should be doing, whereas
diaries or questionnaires would be expected to be heavily influenced by preconceived ideas of what
is required when reporting to the study personnel. In this case, plasma alkylresorcinols may better
reflect what is actually going on and be a more reliable indicator of compliance. Several studies
have established that plasma alkylresorcinols do respond rapidly to intake of wholegrain wheat and
rye [35], and that regular consumption of whole grains under controlled conditions leads to stable and
repeatable elevated fasting plasma concentrations [44]. While inter-individual variation is high, and
many factors can influence plasma alkylresorcinol concentration beyond intake of whole grains [35,45],
it is highly unlikely that someone eating 80 g of whole-grain foods, mainly wheat, would have plasma
total alkylresorcinol concentrations <70 nmol/L. Plasma alkylresorcinols would not detect if a person
ate mainly oat- or rice-based products, though subjects on the whole-grain intervention reported eating
mainly wheat products, the minimum amount being 64%, equivalent to 50 g/day of whole-grain
wheat. Even if a subject only chose to eat all their whole grain at breakfast time, giving the maximum
amount of time for concentrations to return to baseline, fasting concentrations still remain higher 24 h
later than a non-whole-grain diet (Ross et al., under preparation). Although on a group basis there was
a difference in plasma alkylresorcinol measurements, this was largely driven by relatively few subjects
with very high concentrations. A similar result was seen in another large study where whole-grain
foods were provided in an open setting, where although mean alkylresorcinol concentrations differed,
a large proportion of individuals had very low concentrations that would be unlikely based on results
from controlled whole-grain trials where alkylresorcinols have been measured [35]. So, while it is
not possible to rule out that subjects were actually compliant even with low plasma alkylresorcinol
concentrations, based on the high proportion of whole-grain wheat products consumed in the detailed
analysis of a subset of subjects, the overall high amount of whole grains reported as being eaten
(mean 124 g/day) and what is known from controlled whole-grain feeding studies, we have to raise
strong doubts about the subjects’ compliance to the diet. The alkylresorcinol concentrations suggest
that compliance was so low that no conclusions on the relationship of whole grains and weight regain
after weight loss that can be made from this study.
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If there was an apparent problem of compliance to the whole-grain diet, it is necessary to attempt
to explain why. Personalised nutritional advice was provided to the subjects to maintain a healthy diet,
and this may have aided subjects in not overeating after the weight loss period. This added awareness
and support for eating a healthy diet could reduce any potential effect of whole grains on satiety or
satiation compared to refined grains. Foods provided were commercially available in the country where
the study was carried out, and considered to be organoleptically acceptable. No difference in taste
preference or gastrointestinal comfort between the diets was reported by the participants, although the
higher dropout rate in the WG group may indicate that the subjects were less willing to eat foods that
were not part of their habitual diet. Another factor may be that subjects, having lost weight in the first
part of the study, attempted to maintain a reduced energy diet to maintain the weight loss, and avoided
eating the study products they collected. This is supported by the lack of any appreciable weight gain
over the 3-month diet intervention period. The energy derived from the intervention products would
have made up a considerable proportion of their total intake when compliant, and not consuming
the intervention products, or consuming them in reduced amounts, would have a major effect on
overall energy intake. It has previously been shown that a high intake of intervention foods providing
~100 g whole grains per day is possible during weight loss [23]. The design applied here was different,
however, as an 8-week LCD phase was applied prior to the dietary intervention, where differences in
weight regain were targeted. A low weight regain during the 12-week intervention period was seen in
both groups, which makes it difficult to detect potentially subtle differences between groups. A similar
design was applied in the DIOGENES pan-European study, but weight regains were larger, and the
intervention period lasted 6 months rather than 12 weeks [46]. Thus, a longer study period may have
produced different results. Finally, the French population are not habitual whole-grain consumers
in general [47] and the participants were recruited on the basis of being non-whole-grain consumers
(<16 g whole grains/day), as we expected a change towards a high whole-grain intake to benefit
non-consumers the most. The fact that the participants were not accustomed to the whole-grain foods
may have been a disadvantage rather than an advantage, as it may affect the participants’ willingness
to incorporate the unfamiliar foods into their diet, resulting in poor compliance. Supporting this
theory, a study carried out by Kristensen et al. (2012) in Denmark [23], where the whole-grain intake is
among the highest in the world, did not prevent significant differences being observed resulting from
participants eating a whole-grain or refined-grain diet. In the U.K., the WHOLEHEART study was
conducted in a group of ~300 non-whole-grain consumers [29]. Here, the participants were allocated
to three different groups (0, 80, and 160 g of whole grains/day), and they found that particularly the
participants consuming the most whole grain tended to increase their overall energy intake, indicating
that substitution of habitual foods was difficult. In the present study, the dietary intake data do not,
however, show that participants in the WG group consumed more energy than those randomised
to the RG group. Given that the same dietary data indicated that average whole-grain intake was
>100 g/day, we have reason to doubt the reliability of the dietary intake data. Beyond an issue with
compliance to the whole-grain diet, is that neither group gained the expected amount of weight after
the 3-month dietary intervention. This suggests that subjects in both groups were not compliant,
adding weight to the hypothesis that lack of compliance was due to a desire of the subjects to maintain
weight loss, rather than a specific aversion to the whole-grain products provided. Although plasma
alkylresorcinols can detect the difference between whole-grain, refined-grain wheat, and gluten-free
diets [48], they would be unlikely to detect non-compliance to the control diet, as all subjects were
likely to be regular consumers of refined wheat-based foods since they were recruited on the basis of
being low-whole-grain consumers. Further, there was no difference between plasma alkylresorcinol
measurements at any of the three time points for the control group.
Although compliance was highlighted as a problem in this study, analysis using ITT or CC did
not change any of the outcomes. These do not reflect the measured compliance according to plasma
alkylresorcinols, so post hoc analyses were performed, using plasma alkylresorcinol concentrations in
place of whole-grain intake based on diet records. As the number of subjects that could be considered
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to be compliant was low (n = 106), the resulting statistical power of the post hoc analyses was far lower
than that calculated as necessary to find a difference between groups. Weak trends were observed
for regression models for plasma alkylresorcinols and a reduction in body fat, but these were not
consistent between different measures of abdominal fat, suggesting that the available power from
compliant subjects was insufficient for the study outcome.
This study highlights the broader issue of inconsistency of results from dietary intervention
studies—both for whole grains [49] and in general. While most studies do include compliance
checks—including diaries, questionnaires, and collection of empty packaging—unless the subjects are
observed eating their intervention products, it is very difficult to guarantee if subjects have actually
followed the requested protocol, including whether they have replaced or added intervention foods to
their regular diet. Although dietary biomarkers are frequently called for, their actual use in intervention
studies remains limited, in part because although there is much work on discovery of these biomarkers,
there is less work on their validation—research which is essential for biomarkers to be used to ensure
compliance. While biomarkers are useful for ensuring that study outcomes are trustworthy from a
compliance perspective, it should be remembered that they remain an “ambulance at the bottom of the
cliff”—once they highlight the problem, the study is likely to have been finished long ago. More work
needs to be done during a study to ensure compliance, and under ideal circumstances, biomarker
measurements should be made during the course of a long-term study so that direct feedback can be
given to the subjects. Although there are many barriers to this at present, with time it could become
standard procedure to check compliance based on several biomarkers throughout the course of a
nutrition intervention study.
5. Conclusions
In conclusion, this study, designed to test if a whole-grain diet leads to lower body weight regain
after weight loss, was hampered by a high level of non-compliance, and does not allow any conclusion
to be made about the role of whole grains and body weight and body composition. This study does
highlight the importance of including biomarkers of intake in nutrition intervention studies, which
has provided clear evidence that the study has not tested the hypothesis it was designed to do. We are
able to highlight a weakness in this type of study design if subjects are highly motivated to maintain
weight loss, and the consequent importance of incorporating a biomarker of food intake to allow
post hoc validation of compliance. Further studies are needed to address the tantalising findings of
some intervention studies that whole grains may positively impact on body composition, and these
should place extra weight on ensuring compliance to the recommended diet beyond self-report during
the study.
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